Skip to main content

The principal mission of the Institut Bordet Department of Surgery is the surgical treatment of cancerous diseases.

More specifically, our surgeons strive to:

  • offer leading-edge surgical techniques in the treatment of cancer;
  • integrate surgery into global cancer treatment;
  • encourage approaches combining surgery and other treatments such as chemotherapy, radiotherapy, nuclear medicine, interventional radiology, immunotherapy, etc;
  • promote research and develop innovative treatments;
  • collaborate at national and international levels with other cancer centres;
  • teach surgery to medical students and future surgeons;
  • train surgeons specifically in oncological surgery.

The Institut Bordet Department of Surgery comprises 6 specific fields:

  • Cervicofacial and Thoracic Surgery
  • Digestive Surgery
  • Breast and Pelvic Surgery
  • Bone and Connective Tissue Tumour Surgery
  • Cancer Reconstructive Surgery
  • Skin Tumour Surgery.

Research projects

Project 1

Study of the contribution of Fluorescence Imaging in the diagnosis and staging of cancer.
  • Collaborations : Group R&D for the Clinical Application of Fluorescence Imaging, Institut Jules Bordet
  • Funding : Les Amis de l'Institut Bordet

Project 2

Study of immunogenicity and immune response in hepatocellular carcinoma.

Project 3

Identification of oligometastatic profiles in colorectal cancer: creation of a multidisciplinary platform.

Project 4

Evaluation of metabolic and pathological response after radio-chemotherapy and immunotherapy in advanced oesophageal and oesogastric junction cancers (ARTemIS)

Our team

Head of Department
Prof Vincent Donckier

Digestive Surgery
Pr Gabriel Liberale, Head of Clinic

Pr Vincent Donckier
Dr Fikri Bouazza
Pr Issam El Nakadi

Dr Florin Catalin Pop
Pr Jean Van de Stadt

Cervicofacial and Thoracic Surgery
Dr Antoine Digonnet, Head of Clinic
Dr Esther Willemse
Dr Marie Quiriny
Dr Samuel Lipski (ENT specialist)
Dr Cécile Dekeyser (ENT specialist)
Pr Guy Andry, Honorary Professor of Surgery

Breast and Pelvic Surgery
Dr Isabelle Veys, Head of Clinic
Dr Danièle Noterman
Dr Filip De Neubourg
Dr Mirela Roman
Pr Jean Marie Nogaret

Dr Florin Catalin Pop

Cancer Reconstructive Surgery
Dr Frédéric Urbain, Head of Clinic
Dr Simona Brondello
Dr Dimitri Tsepelidis

Dr Marta Misani 

Skin Tumour Surgery
Dr François Sales, Head of Clinic
Dr Marie Quiriny

Bone and Connective Tissue Tumour Surgery
Dr Felix Shumelinsky, Head of Clinic

Dr Bilal Kapanci
Pr Michael Gebhart

Senior Nurses – In-patient unit
Ingrid Bruyns
Fabienne Van Ginderachter

Secretariat
Marylène Boulet

Laurence Wanet

13/05/2020

 Scientific publications

Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration.

Authors : Bouland C, Philippart P, Dequanter D, Corrillon F, Loeb I, Bron D, Lagneaux L, Meuleman N
Year : 2021
Journal : Front Cell Dev Biol
Volume : 9
Pages : 674084

The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases - Belgian Group for Digestive Oncology (BGDO).

Authors : Bohlok A, Derijckere ID, Azema H, Lucidi V, Vankerckhove S, Hendlisz A, Laethem JLV, Goldman S, Flamen P, Larsimont D, Demetter P, Dirix L, Vermeulen P, Donckier V
Year : 2021
Journal : Ann Hepatobiliary Pancreat Surg
Volume : 25
Pages : S63

Buschke-Löwenstein tumor in a human immunodeficiency virus-positive patient: a case report and short literature review.

Authors : Ledouble V, Sclafani F, Hendlisz A, Gomez Galdon M, Liberale G
Year : 2021
Journal : Acta Gastroenterol Belg
Volume : 84
Pages : 343-345

Is Endovascular Retroperitoneoscopic Aortobifemoral Bypass a Reasonable Alternative to Transperitoneal Open Surgery for Treatment of Severe Aorto-Iliac Occlusive Lesions? A Retrospective Comparative Analysis.

Authors : Segers B, Solari L, Ferrera J, Sosnowski M, Wautrecht JC, Donckier V
Year : 2021
Journal : Eur J Vasc Endovasc Surg
Volume : 62
Pages : 489-490

MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways.

Authors : Augenlicht A, Saiselet M, Decaussin-Petrucci M, Andry G, Dumont JE, Maenhaut C
Year : 2021
Journal : Oncotarget
Volume : 12
Pages : 1587-1599